Amgen's stock plunges after early trial data suggests its weight loss drug, MariTide, may decrease bone density.

Amgen's stock dropped over 7% after data from an early-stage trial of its experimental weight loss drug, MariTide, showed a potential 4% decrease in bone mineral density over 12 weeks. While some analysts see this as a safety risk, others argue it's an overreaction and call for more data. MariTide aims to be taken monthly, unlike weekly treatments from competitors. Wall Street awaits phase two trial results expected by year-end.

November 12, 2024
14 Articles

Further Reading